Guideline-Directed Medical Therapy for HFrEF
All patients with HFrEF (LVEF ≤40%) should be initiated on quadruple therapy consisting of four foundational drug classes: an ARNI (angiotensin receptor-neprilysin inhibitor) or ACE inhibitor/ARB, a beta blocker, a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor (sodium-glucose cotransporter-2 inhibitor), with target dose titration within 6-12 weeks of diagnosis. 1, 2
The Four Pillars of HFrEF Treatment
The 2022 AHA/ACC/HFSA guidelines establish these four medication classes as the new standard of care, representing a paradigm shift from sequential therapy to rapid quadruple therapy initiation 1, 2, 3:
1. ARNI (Preferred) or ACE Inhibitor/ARB
- ARNI (sacubitril-valsartan) is preferred as first-line therapy over ACE inhibitors or ARBs due to superior mortality and morbidity reduction 3
- If starting with ACE inhibitor/ARB, transition to ARNI once stabilized
- ARNI demonstrates significant left ventricular reverse remodeling, with LVEF improvements of +42.1% and reductions in LV volumes 4
2. Evidence-Based Beta Blockers
- Carvedilol, metoprolol succinate, or bisoprolol
- 92% of patients receive beta blockers within 3 months of diagnosis 5
3. Mineralocorticoid Receptor Antagonists (MRA)
- Spironolactone or eplerenone
- Implementation remains suboptimal: only 35-46% of eligible patients receive MRAs 5
4. SGLT2 Inhibitors
- Dapagliflozin or empagliflozin
- This represents the newest addition to foundational therapy 1
- Current real-world use ranges from 19-30%, indicating significant room for improvement 5
Implementation Strategy
Timing and Sequencing
Initiate all four drug classes as early as possible—ideally within the first 6 weeks of diagnosis 6, 7. The TITRATE-HF study demonstrates that:
- Early quadruple therapy (within 6 weeks) achieves 47.2% implementation in de novo HFrEF 7
- This increases to 64.7% at 3 months and 69.5% at 6 months 7
- Early initiation and higher 6-month doses correlate with greater LVEF improvement 7
Dose Titration
- Target maximally tolerated doses within 6-12 weeks 6
- Higher doses at 6 months are independently associated with better LVEF recovery 7
- Continue dose optimization beyond the initial phase—don't stop at "stable" doses 7
Clinical Outcomes
The composite endpoint of all-cause death or HF hospitalization at 12 months occurs in:
- 13.3% of de novo HFrEF patients on optimized GRMT 7
- 43.8% of worsening HFrEF patients, emphasizing the importance of early intervention 7
Secondary Therapies for Specific Indications
Beyond the foundational four, consider these agents for persistent symptoms or specific clinical scenarios 6, 3:
- Ivabradine: For sinus rhythm with heart rate ≥70 bpm despite beta blocker optimization
- Hydralazine/isosorbide dinitrate: Particularly beneficial in Black patients or when ARNI/ACE inhibitor/ARB contraindicated
- Vericiguat: For worsening HF despite GDMT (soluble guanylate cyclase stimulator)
- Digoxin: For persistent symptoms or atrial fibrillation with rate control needs
Common Pitfalls and Management
Adverse Effect Management
Do not prematurely discontinue or avoid uptitration due to common, manageable adverse effects 6:
- Hypotension: Often asymptomatic; tolerate systolic BP to 90 mmHg if no symptoms
- Hyperkalemia: Adjust MRA dose, optimize other medications, consider potassium binders
- Worsening kidney function: Accept creatinine increases up to 30% if stable thereafter
Real-World Implementation Gaps
Despite strong evidence, significant underutilization persists 5:
- Only 18-22% receive ARNI (versus ACE inhibitor/ARB) even >12 months after diagnosis
- MRA use plateaus at 46% in chronic HFrEF
- SGLT2 inhibitor adoption remains at 26-30%
These gaps represent missed opportunities for mortality reduction and LVEF improvement.
Special Considerations
Improved LVEF (Previously HFrEF, Now >40%)
Continue all HFrEF therapies even after LVEF improvement 1. Discontinuation risks deterioration back to HFrEF.
LVEF Recovery Expectations
In de novo HFrEF with serial echocardiograms 7:
- Median LVEF improvement: 10% (IQR 3-17%) in ischemic cardiomyopathy
- Median LVEF improvement: 15% (IQR 9-24%) in non-ischemic cardiomyopathy
- Lower baseline LVEF predicts greater absolute LVEF recovery 4
Inpatient Initiation
Hospitalization for HF is an opportunity, not a contraindication, for GDMT initiation 3. Begin therapy during admission and arrange close outpatient follow-up for titration.
Monitoring and Follow-Up
- Reassess at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months
- Check electrolytes and renal function 1-2 weeks after each dose adjustment
- Repeat echocardiography at 3-6 months to assess LVEF response
- Continuous dose titration beyond initial stabilization improves outcomes 7